Oxolinic acid |
|
| AHFS/Drugs.com | International Drug Names |
|---|
| ATC code | |
|---|
|
5-Ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline- 7-carboxylic acid
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.035.213 |
|---|
|
| Formula | C13H11NO5 |
|---|
| Molar mass | 261.233 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
CCN1C=C(C(=O)C2=CC3=C(C=C21)OCO3)C(=O)O
|
InChI=1S/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17) NKey:KYGZCKSPAKDVKC-UHFFFAOYSA-N N
|
N Y (what is this?) (verify) |
Oxolinic acid is a quinolone antibiotic developed in Japan in the 1970s.[1][2] Dosages 12–20 mg/kg orally administered for five to ten days. The antibiotic works by inhibiting the enzyme DNA gyrase. It also acts as a dopamine reuptake inhibitor and has stimulant effects in mice.[3]
See also
- Amfonelic acid
- Fluoroquinolone
References
- ^ JP Patent 49138244
- ^ Gleckman R, Alvarez S, Joubert DW, Matthews SJ (August 1979). "Drug therapy reviews: oxolinic acid". American Journal of Hospital Pharmacy. 36 (8): 1077–9. PMID 384788.
- ^ Garcia de Mateos-Verchere J, Vaugeois JM, Naudin B, Costentin J (December 1998). "Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor". European Neuropsychopharmacology. 8 (4): 255–9. doi:10.1016/S0924-977X(97)00083-7. PMID 9928913. S2CID 22626555.
Antibacterials that inhibit nucleic acid (J01E, J01M) |
|---|
Antifolates (inhibit bacterial purine metabolism, thereby inhibiting DNA and RNA synthesis) | | DHFR inhibitor | |
|---|
Sulfonamides (DHPS inhibitor) | | Short-acting | |
|---|
| Intermediate-acting | |
|---|
| Long-acting | |
|---|
| Other/ungrouped | |
|---|
|
|---|
| Combinations | |
|---|
| Other DHPS inhibitors | |
|---|
|
|---|
Quinolones (inhibit bacterial topoisomerase and/or DNA gyrase, thereby inhibiting DNA replication) | | 1st generation | |
|---|
| Fluoroquinolones | | 2nd generation | |
|---|
| 3rd generation | |
|---|
| 4th generation | |
|---|
| Veterinary | |
|---|
|
|---|
| Newer non-fluorinated | |
|---|
| Related (DG) | |
|---|
|
|---|
Anaerobic DNA inhibitors | | Nitroimidazole derivatives | |
|---|
|
|---|
| RNA synthesis | Rifamycins/ RNA polymerase | |
|---|
| Lipiarmycins | |
|---|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
Dopamine receptor modulators |
|---|
| D1-like | | Agonists |
- Benzazepines: 6-Br-APB
- Fenoldopam
- SKF-38,393
- SKF-77,434
- SKF-81,297
- SKF-82,958
- SKF-83,959
- Trepipam
- Zelandopam
- Dihydrexidine derivatives: A-77636
- A-86929
- Adrogolide (ABT-431, DAS-431)
- Dihydrexidine
- Dinapsoline
- Dinoxyline
- Doxanthrine
- Phenethylamines: BCO-001
- Deoxyepinephrine (N-methyldopamine, epinine)
- Dipropyldopamine (DPDA)
- Dopamine
- Dopexamine
- Etilevodopa
- Ibopamine
- L-DOPA (levodopa)
- Lu AE04621
- Melevodopa
- L-Phenylalanine
- L-Tyrosine
- XP21279
- Others: A-68930
- Apomorphine
- Isocorypalmine
- Lu AF28996
- Nuciferine
- PF-06412562
- PF-6649751
- PF 6669571
- Propylnorapomorphine
- Rotigotine
- SKF-89,145
- SKF-89,626
- Stepholidine
- Tavapadon
- Tetrahydropalmatine
|
|---|
| PAMs |
- Tetrahydroisoquinolines: DETQ
- DPTQ
- Glovadalen
- Mevidalen
|
|---|
| Antagonists |
- Others: Berupipam
- Ecopipam
- EEDQ
- Metitepine (methiothepin)
- Odapipam
- Perlapine
- SCH-23390
|
|---|
|
|---|
| D2-like | | Agonists |
- Aminotetralins: 5-OH-DPAT
- 7-OH-DPAT
- 8-OH-PBZI
- CHF-1024
- Nolomirole
- Rotigotine
- UH-232
- Dihydrexidine derivatives: 2-OH-NPA
- Ciladopa
- Dihydrexidine
- Dinoxyline
- N,N-Propyldihydrexidine
- Phenethylamines: Deoxyepinephrine (N-methyldopamine, epinine)
- Dipropyldopamine (DPDA)
- Dopamine
- Dopexamine
- Etilevodopa
- Ibopamine
- L-DOPA (levodopa)
- Lu AE04621
- L-Phenylalanine
- RU-24213
- L-Tyrosine
- Melevodopa
- XP21279
- Atypical antipsychotics: Alentemol (U-66444B)
- Aripiprazole (+sertraline)
- Aripiprazole lauroxil
- Bifeprunox
- Brexpiprazole
- Brilaroxazine
- Cariprazine
- F-15063
- Lumateperone
- Norclozapine
- Others: 3-PPP
- A-412997
- ABT-670
- ABT-724
- Adrafinil
- Aplindore
- Apomorphine
- Arketamine
- Armodafinil
- BP-897
- Captodiame
- CP-226,269
- Debenzergoline
- Dizocilpine
- Esketamine
- Etrabamine
- Flibanserin
- 7-Hydroxyropinirole (SK&F-89124)
- Ketamine
- Lu AF28996
- Matsupexole
- Modafinil
- Naxagolide
- OSU-6162
- Pardoprunox
- PD-128,907
- PD-168,077
- PF-219,061
- PF-592,379
- Phencyclidine
- Piribedil
- Pramipexole
- Preclamol
- Propylnorapomorphine
- Pukateine
- Quinagolide
- Quinelorane
- Quinpirole
- RDS-127
- Ro10-5824
- Ropinirole
- Roxindole
- S32504
- Salvinorin A
- SKF-39315
- SKF-83,959
- Sumanirole
- Talipexole
- Umespirone
- WAY-100,635
- XC-130
|
|---|
| Antagonists |
- Others: 3-PPP
- Alpiropride
- Azapride
- Bromerguride
- Bromocriptine
- Buspirone
- Carmoxirole
- Desmethoxyfallypride
- EEDQ
- F-15063
- Fallypride
- Fananserin
- Fenfluramine
- Iodobenzamide
- Isocorypalmine
- L-741,626
- L-745,870
- Levofenfluramine
- LEK-8829
- Metitepine (methiothepin)
- N-Methylspiperone
- Nafadotride
- Nuciferine
- Ordopidine
- PNU-99,194
- Pridopidine
- Raclopride
- Sarizotan
- SB-277,011-A
- Seridopidine
- Sonepiprazole
- Spiroxatrine
- Stepholidine
- SV-293
- Tetrahydropalmatine
- Tiapride
- UH-232
- XC-130
- Yohimbine
|
|---|
|
|---|
- See also: Receptor/signaling modulators
- Adrenergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
|
Authority control databases |
|---|
| International | |
|---|
| National | |
|---|